Quoin Pharmaceuticals on the Brink: Nasdaq Deficiency Notice Threatens Stability and Investor Confidence
Company Announcements

Quoin Pharmaceuticals on the Brink: Nasdaq Deficiency Notice Threatens Stability and Investor Confidence

Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Quoin Pharmaceuticals Ltd. is grappling with a serious business risk that could significantly impact its financial stability and investor relations. On April 29, 2024, the company received a deficiency notice from Nasdaq due to its failure to meet the Minimum Bid Price Requirement over a span of 31 consecutive business days. Quoin Pharmaceuticals has until October 28, 2024, to regain compliance or face potential delisting. Such an outcome could severely limit market liquidity, reduce the company’s ability to raise capital, and erode investor confidence.

The average QNRX stock price target is $7.00, implying 805.97% upside potential.

To learn more about Quoin Pharmaceuticals Ltd’s risk factors, click here.

Related Articles
TipRanks Auto-Generated NewsdeskQuoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges
TheFlyQuoin Pharmaceuticals reports Q3 EPS ($1.63), consensus (49c)
TheFlyQuoin Pharmaceuticals sees cash runway into late 2025
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App